Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Stock analysts at Roth Capital cut their Q1 2025 earnings per share estimates for Curaleaf in a research report issued to clients and investors on Thursday, May 1st. Roth Capital analyst W. Kirk now anticipates that the company will earn ($0.07) per share for the quarter, down from their previous estimate of ($0.06). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Curaleaf's FY2025 earnings at ($0.25) EPS and FY2026 earnings at ($0.21) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.09. The firm had revenue of $331.05 million during the quarter, compared to the consensus estimate of $331.87 million. Curaleaf had a negative return on equity of 13.67% and a negative net margin of 14.82%.
Curaleaf Stock Performance
CURLF traded down $0.00 during trading on Monday, hitting $0.93. 486,474 shares of the company traded hands, compared to its average volume of 707,089. Curaleaf has a one year low of $0.68 and a one year high of $6.01. The stock's fifty day moving average is $0.92 and its 200 day moving average is $1.51. The company has a quick ratio of 0.51, a current ratio of 1.11 and a debt-to-equity ratio of 0.85. The firm has a market cap of $616.18 million, a P/E ratio of -3.21 and a beta of 0.83.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Recommended Stories
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
